Purpose of Review

The objective of this manuscript is to examine the current literature on non-alcoholic fatty liver disease (NAFLD) biomarkers and their correlation with cardiovascular disease (CVD) outcomes and cardiovascular risk scores.

Recent Findings

There has been a growing appreciation for an independent link between NAFLD and CVD, culminating in a scientific statement by the American Heart Association in 2022. More recently, studies have begun to identify biomarkers of the three NAFLD phases as potent predictors of cardiovascular risk.

Summary

Despite the body of evidence supporting a connection between hepatic biomarkers and CVD, more research is certainly needed, as some studies find no significant relationship. If this relationship continues to be robust and readily reproducible, NAFLD and its biomarkers may have an exciting role in the future of cardiovascular risk prediction, possibly as risk-enhancing factors or as components of novel cardiovascular risk prediction models.

中文翻译：

---

肝功能障碍和心血管风险的生物标志物

审查目的

本手稿的目的是检查有关非酒精性脂肪肝疾病 (NAFLD) 生物标志物及其与心血管疾病 (CVD) 结果和心血管风险评分的相关性的当前文献。

最近的发现

人们越来越认识到 NAFLD 和 CVD 之间的独立联系，最终美国心脏协会于 2022 年发表了一份科学声明。最近，研究已开始确定 NAFLD 三个阶段的生物标志物作为心血管风险的有效预测因子。

概括

尽管有大量证据支持肝脏生物标志物与心血管疾病之间的联系，但肯定需要更多的研究，因为一些研究发现没有显着的关系。如果这种关系继续保持稳健且易于重现，NAFLD 及其生物标志物可能在未来的心血管风险预测中发挥令人兴奋的作用，可能作为风险增强因素或作为新型心血管风险预测模型的组成部分。